Case studies
Named outcomes, honest constraints and the parts that took longer than planned.
Commercial · Biopharma
Replacing eleven fragmented reporting stacks with one governed foundation and an agent layer the field actually uses.
11 → 1
Reporting stacks retired
-94%
Reconciliation time
81%
Field adoption
Clinical · Clinical research
Cross-source anomaly detection across EDC, labs and eCOA that cut query volume while catching issues sooner.
11 days
Earlier detection
-38%
Query volume
-21%
Monitoring cost
Research · Discovery research
A harmonised omics layer with sample-level provenance that scientists trusted enough to publish from.
weeks → minutes
Cohort build
40+
Sources unified
100%
Reproducibility
Manufacturing · Manufacturing
Simulating supply disruption ahead of launch and pre-positioning inventory against the highest-risk paths.
1,400
Scenarios modelled
$6.2M
Buffer cost avoided
0
Launch stock-outs
Commercial · Biotech
Continuous payer policy monitoring turned reactive access defence into prepared evidence delivery.
6 weeks
Average warning
-71%
Manual review
4.1M
Covered lives protected
Regulatory · Biopharma
Guidance change monitoring mapped directly to affected submission components and owners.
-58%
Review effort
Traceability
Missed changes
Next step
Thirty minutes with our architects is usually enough to tell whether a programme is ready for agents, or whether the data foundation needs work first.